In a retrospective study of 163 patients with HER2-negative hormone-positive breast cancer, everolimus combined with hormonotherapy led to a median PFS of 9 and 10 months for 10 mg/day and 5 mg/day doses, respectively [20]. The gene discussed is ERBB2; the disease is breast cancer.